Last reviewed · How we verify

Clonorchiasis due to C. Sinensis — Treatment Landscape & Competitive Intelligence

Clonorchiasis due to C. Sinensis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Clonorchiasis due to C. Sinensis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cysticide Cysticide Merck KGaA, Darmstadt, Germany Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck KGaA, Darmstadt, Germany · 1 drug in Clonorchiasis due to C. Sinensis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Clonorchiasis due to C. Sinensis:

Cite this brief

Drug Landscape (2026). Clonorchiasis due to C. Sinensis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/clonorchiasis-due-to-c-sinensis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing